| Siltuximab and Spartalizumab in Patients With Metastatic Pancreatic Cancer |
Recruiting |
Metastatic Pancreatic Adenocarcinoma|Stage IV Pancreatic Cancer AJCC v8 |
NCT04191421 |
| Modulation of STAT3 Signaling With Siltuximab in Type 1 Diabetes |
Completed |
Type 1 Diabetes |
NCT02641522 |
| Siltuximab to Decrease Symptom Burden After Autologous Stem Cell Transplantation for Patients With Multiple Myeloma and AL Amyloidosis |
Active, not recruiting |
Multiple Myeloma|AL Amyloidosis |
NCT03315026 |
| A Study to Evaluate the Safety of Long-term Treatment With Siltuximab in Patients With Multicentric Castleman's Disease |
Completed |
Multicentric Castleman's Disease |
NCT01400503 |
| Siltuximab in Treating Patients With Primary, Post-Polycythemia Vera, or Post-Essential Thrombocythemia Myelofibrosis |
Withdrawn |
Myelofibrosis|Polycythemia Vera|Primary Myelofibrosis|Thrombocytopenia |
NCT02805868 |
| Siltuximab in Schizophrenia |
Recruiting |
Schizophrenia|Psychotic Disorders |
NCT02796859 |
| A Phase 1 Study of CNTO 328 (Siltuximab) in Relapsed or Refractory Multiple Myeloma |
Terminated |
Multiple Myeloma |
NCT01309412 |
| A Study of Siltuximab (Anti- IL 6 Monoclonal Antibody) in Patients With High-risk Smoldering Multiple Myeloma |
Completed |
High-risk Smoldering Multiple Myeloma |
NCT01484275 |
| A Study Evaluating the Effects of Siltuximab on the Heart in Patients With Monoclonal Gammopathy of Undetermined Significance, Smoldering Multiple Myeloma, or Indolent Multiple Myeloma |
Completed |
Monoclonal Gammopathy of Undetermined Significance|Multiple Myeloma|Plasma Cell Neoplasm |
NCT01219010 |
| A Study Comparing Siltuximab Plus Best Supportive Care to Placebo Plus Best Supportive Care in Anemic Patients With International Prognostic Scoring System Low- or Intermediate-1-Risk Myelodysplastic Syndrome |
Terminated |
Myelodysplastic Syndrome |
NCT01513317 |
| A Phase 3 Study of Siltuximab or Placebo in Combination With Velcade and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma |
Withdrawn |
Multiple Myeloma |
NCT01266811 |
| An Observational Case-control Study of the Use of Siltuximab in ARDS Patients Diagnosed With COVID-19 Infection |
Recruiting |
Severe Acute Respiratory Syndrome (ARDS) Secondary to SARS-COV-2 Infection |
NCT04322188 |
| Lenalidomide/Bortezomib/Dexamethasone & CNTO 328 in Transplant Eligible Newly Diagnosed Multiple Myeloma (MM) |
Completed |
Myeloma |
NCT01531998 |
| An Efficacy and Safety Study of Siltuximab in Participants With Relapsed or Refractory Multiple Myeloma |
Completed |
Multiple Myeloma |
NCT00402181 |
| A Safety and Efficacy Study of Siltuximab (CNTO 328) in Male Subjects With Metastatic Hormone-Refractory Prostate Cancer (HRPC) |
Terminated |
Cancer, Prostate |
NCT00385827 |
| A Safety, Efficacy and Pharmacokinetic Study of Siltuximab (CNTO 328) in Participants With Solid Tumors |
Completed |
Ovarian Neoplasms|Pancreatic Neoplasms|Colorectal Neoplasms|Head and Neck Neoplasms|Lung Neoplasms |
NCT00841191 |
| A Study to Evaluate the Efficacy and Safety of CNTO328 Plus Best Supportive Care in Multicentric Castleman's Disease |
Completed |
Multicentric Castleman's Disease |
NCT01024036 |
| A Study of the Safety and Efficacy of CNTO 328 and Bortezomib to Bortezomib Alone in Patients With Relapsed or Refractory Multiple Myeloma |
Completed |
Multiple Myeloma |
NCT00401843 |
| S0354, Anti-IL-6 Chimeric Monoclonal Antibody in Patients With Metastatic Prostate Cancer That Did Not Respond to Hormone Therapy |
Completed |
Prostate Cancer |
NCT00433446 |
| A Study to Compare CNTO 328 (Anti-IL-6 Monoclonal Antibody) and VELCADE-Melphalan-Prednisone (VMP) With VMP Alone in Previously Untreated Multiple Myeloma Patients |
Completed |
Multiple Myeloma |
NCT00911859 |
| S0351, CNTO 328 in Treating Patients With Unresectable or Metastatic Kidney Cancer |
Withdrawn |
Kidney Cancer |
NCT00311545 |
| A Study to Assess the Safety and Pharmacokinetics of a Single Intravenous Administration of CNTO 328 Derived From 2 Different Cell Lines in Healthy Participants |
Completed |
Healthy |
NCT02074800 |
| Tocilizumab in Schizophrenia |
Recruiting |
Schizophrenia|Psychotic Disorders |
NCT02874573 |
